The landscape of mental health treatment is on the cusp of a profound transformation, with psilocybin, a compound once relegated to Schedule I of the Controlled Substances Act, poised for potential FDA approval. This historic shift, decades in the making, promises new hope for patients suffering from treatment-resistant depression (TRD) but also introduces complex questions for the healthcare and insurance sectors. While the scientific and regulatory hurdles are steadily being cleared, the practicalities of integrating psilocybin into mainstream medical practice — particularly from an underwriting perspective — present a unique set of challenges and opportunities.
From Schedule I to Breakthrough Therapy: Psilocybin’s Journey
For over fifty years, psilocybin, the psychoactive component found in "magic mushrooms," has been classified by the federal government alongside substances like heroin, deemed to have no accepted medical use and a high potential for abuse. This classification, established with President Richard Nixon’s signing of the Controlled Substances Act in 1970, effectively halted most legitimate research into its therapeutic potential for decades. However, a resurgence of scientific interest in the late 20th and early 21st centuries, fueled by growing evidence of its efficacy in treating various mental health conditions, has propelled psilocybin back into the spotlight.
The current momentum is largely driven by companies like Compass Pathways, a mental health care company focused on accelerating patient access to evidence-based innovation. Their synthetic psilocybin formulation, COMP360, has achieved significant milestones, particularly for treatment-resistant depression, a severe form of depression that does not respond to conventional therapies. TRD affects millions globally, with estimates suggesting that up to one-third of individuals with major depressive disorder may experience TRD. The profound unmet medical need in this population underscores the urgency and potential impact of new treatment modalities.
Regulatory Milestones Pave the Way for FDA Approval
Compass Pathways’ COMP360 has successfully met its primary endpoint in two Phase 3 trials for TRD, a critical step towards regulatory approval. The company is now navigating the final stages of the approval process, having been granted a rolling New Drug Application (NDA) review by the FDA in April [2026]. This allows Compass Pathways to submit sections of its application as they are completed, rather than waiting for the entire package, potentially accelerating the review timeline.
Further signaling the FDA’s recognition of psilocybin’s potential, COMP360 was also awarded a Commissioner’s National Priority Voucher (CNPV). This new pathway is designed to expedite the review of drugs addressing critical public health needs, potentially compressing a standard 10-to-12-month review period to as little as one or two months. Such a voucher reflects a high level of priority and confidence from the FDA regarding the compound’s therapeutic promise.
Political support has also aligned with the scientific advancements. In April [2026], President Trump signed an executive order directing federal agencies to accelerate the review and approval of psychedelic treatments for serious mental illnesses. This top-down directive reinforces the regulatory momentum, indicating a concerted effort to bring these therapies to patients more quickly. With these favorable conditions, a first FDA decision on psilocybin could realistically land by late 2026 or early 2027, marking a monumental shift in mental healthcare.
The Underwriter’s Lens: Insuring a Novel Treatment
As psilocybin moves closer to FDA approval, the focus shifts to the practicalities of its integration into the healthcare system, particularly concerning insurance and liability. Jonathan Bound, product development lead at Relm Insurance, a firm that has specialized in underwriting companies within the psychedelics sector for years, offers a critical perspective on what it will take for approved psilocybin to become a viable and insurable business.
Bound’s insights highlight that while FDA approval standardizes aspects of the drug, the unique nature of psychedelic-assisted therapy introduces specific underwriting considerations. The model envisioned for psilocybin treatment typically involves a multi-hour, supervised session, a stark contrast to many traditional pharmaceutical interventions. This extended duration and the profound psychoactive experience necessitate a rigorous approach to risk assessment.
Risk Evaluation and Mitigation Strategies (REMS): A Double-Edged Sword
A key regulatory mechanism that will undoubtedly shape the insurance landscape for psilocybin is the Risk Evaluation and Mitigation Strategy (REMS). The FDA mandates REMS programs for certain drugs with serious safety concerns to ensure that the benefits of the drug outweigh its risks. Spravato (esketamine), an FDA-approved nasal spray for TRD, already operates under a REMS that requires multi-hour monitoring due to its dissociative and sedative effects.
Jonathan Bound explains that while REMS are fundamentally designed to reduce drug-related risks, they simultaneously increase liability sensitivity for healthcare providers. "REMS create specific, documented obligations that must be followed," Bound states. "From an underwriting standpoint, the provider is operating within a federally prescribed risk-control framework. Failure to comply with that framework could support allegations of negligence, professional misconduct, inadequate supervision, improper discharge, or failure to follow required safety protocols." While the insurer wouldn’t be liable for the REMS failure itself, they might have a duty to defend or indemnify covered claims arising from a provider’s noncompliance, subject to policy terms.
Compared to Spravato’s roughly two-hour monitoring, a psilocybin REMS could add incremental exposure due to its potentially longer, full-day supervised session and a more intense psychoactive experience. Bound elaborates, "Longer monitoring increases the period during which the patient is in an altered, vulnerable state and under the provider’s control." This extended vulnerability raises concerns around staffing adequacy, patient supervision, potential boundary violations, employee misconduct, patient elopement, emergency response, psychological destabilization, and premature release. If the REMS imposes specific screening, preparation, monitoring, therapeutic support, documentation, or discharge criteria, the provider’s liability exposure expands to encompass the proper satisfaction of each of these obligations.
Lessons from State-Regulated Programs: Oregon and Colorado
While an FDA-approved psilocybin product would operate under a distinct federal framework, state-regulated programs in places like Oregon and Colorado offer early insights into the real-world application of psilocybin services. These states have legalized psilocybin for therapeutic or adult-use purposes, establishing frameworks that involve supervised administration.
Bound notes the differences: "An FDA-approved medication may involve standardized dosing, clinical labeling, approved indications, provider requirements, REMS obligations, and a more traditional healthcare delivery setting." These features, he suggests, could reduce uncertainty compared with state-regulated adult-use or service-center models, where protocols might be less uniform. However, this standardization also creates new compliance-based liability if providers fail to adhere strictly to required protocols.
Crucially, the claims and demand experience from these nascent state programs remains limited, making precise actuarial assessments challenging. "From an underwriting standpoint, more credible operating and claims data generally allows for more precise risk selection, pricing, and coverage terms over time," Bound explains. "Where data remains limited, insurers typically need to account for uncertainty through underwriting discipline, risk controls, pricing adequacy, and careful attention to sublimits and exclusions." The eventual FDA approval and the subsequent rollout will begin to generate the robust data needed for more refined insurance products.
Operational Challenges and Insurability
The operational model for psilocybin therapy—a multi-hour supervised session with trained monitors—presents significant logistical and cost implications. This "heavy operational and cost model" raises questions about concentration risk (e.g., reliance on specific sites, staffing challenges, facility incidents) and whether it makes the therapy harder to underwrite or scale compared to Spravato’s less intensive workflow.
Bound asserts that while longer supervised sessions inherently increase certain risks, they do not make them "inherently harder to underwrite than shorter supervised sessions." The key, he argues, lies in the standardization and auditability of site-level controls. "The more standardized and auditable those controls are, the easier the risk becomes to underwrite and scale."
He acknowledges the increased exposure to professional liability, premises liability, negligent supervision, employee misconduct, emergency response failures, and improper discharge due to the patient’s extended vulnerable state. However, these exposures "don’t make the model inherently more difficult to insure, they simply require more robust underwriting guidelines." The higher operational costs associated with more staff time, facility capacity, and robust safety controls will naturally translate into higher insurance costs, reflecting the increased risk exposures.
Forging an Insurable Market: The Value Chain
Looking ahead, Relm Insurance anticipates where insurable business will coalesce over the next two to three years. Bound foresees opportunities across the regulated value chain, focusing on entities with defined operating standards. This includes:
- Clinical Research Organizations (CROs): Essential for ongoing research and data collection.
- Drug Developers and Manufacturers: Companies like Compass Pathways producing the approved compound.
- Specialty Distributors: Managing the secure and compliant supply chain.
- Certified Treatment Sites: The clinics and facilities where the therapy will be administered.
- Healthcare Providers: The medical professionals directly involved in patient care.
- Training Organizations: Entities responsible for certifying therapists and monitors in specific psilocybin protocols.
- Ancillary Service Providers: Supporting compliant delivery, such as technology platforms for scheduling or documentation.
Relm’s strategy, according to Bound, has consistently focused on emerging industries where traditional insurance products often fall short. "Psychedelics are a good example of that," he notes. "Beyond simply the compound, the opportunity is the regulated infrastructure needed to responsibly research, manufacture, distribute, administer, and monitor a given treatment."
The Biggest Risk: Market Sustainability
While Compass Pathways’ approval would be a landmark event, the biggest risk from an underwriter’s perspective is not the approval itself, but whether the post-approval ecosystem can become standardized, auditable, and, crucially, financially sustainable.
"The more the market develops around clear protocols, credible clinical governance, and consistent compliance controls; the more underwriters can support it," Bound emphasizes. The greater risk, he warns, "is a market where demand exists, but the operating model remains too expensive, too inconsistent, or too thinly funded to produce a durable insurable market."
This concern is particularly salient given the high operational costs and the need for specialized personnel and facilities. For psilocybin therapy to become widely accessible, reimbursement models from public and private insurers will need to be established, reflecting the true cost and value of the treatment. Without adequate reimbursement, the economic viability of treatment centers could be jeopardized, limiting patient access and ultimately hindering the growth of a robust, insurable market.
Broader Implications for Mental Healthcare
The potential FDA approval of psilocybin represents a paradigm shift for mental healthcare. For millions battling TRD, it offers a novel mechanism of action and potentially more profound and sustained relief than current treatments. The market for psychedelic-assisted therapies is projected to grow significantly, attracting substantial investment and fostering innovation in drug discovery and therapeutic delivery models.
However, the integration of psilocybin will also necessitate a careful balancing act between innovation and patient safety. The detailed REMS, the training and certification of therapists, and the development of specialized treatment facilities will all contribute to a complex but essential infrastructure. The success of this endeavor hinges on robust regulatory oversight, rigorous adherence to protocols by providers, and the willingness of the insurance industry to adapt and provide comprehensive coverage for this emerging frontier in medicine.
In conclusion, the journey of psilocybin from a Schedule I substance to a potential FDA-approved medicine is a testament to scientific perseverance and evolving societal perspectives on mental health. While the medical breakthrough is imminent, the establishment of a fully functional, insurable market requires meticulous attention to operational detail, regulatory compliance, and economic sustainability. The coming years will reveal whether the promise of psilocybin therapy can be fully realized, transforming the lives of patients and reshaping the landscape of mental healthcare.
